Novo dodges a UK Code bullet

Posted 15 April 2024 PM

Novo Nordisk has been cleared by the UK watchdog over claims it drove an "orchestrated PR campaign" to shape the obesity debate - including paying health professionals and various organisations a combined AU$42 million in return for praise for blockbuster drug Wegovy.

There was no official complaint to the Association of British the Pharmaceutical Industry (ABPI) but rather a series of five articles which ran in The Observer newspaper. The headlines included: Orchestrated PR Campaign: how skinny jab drug firm sought to shape the obesity debate and Revealed: Experts who praised new 'skinny jab' firm received payments from drugmaker.

To see the whole article, please login